Global – October 12, 2026 -- ChurnZero has released a Retrospective agent that analyzes activity timelines, engagement signals and health metrics of lost accounts to show why customers churned, as part of its latest platform update.

Retrospective agent targets churn loss analysis

The agent gives customer success teams a data-based review of accounts that have already left. ChurnZero says the findings can help teams spot warning signs sooner in accounts that are currently at risk.

AI agents can now run on demand for single accounts or batches

CSMs can trigger an AI agent from a single account before a call. They can also run one across a batch of accounts wherever account segments support bulk actions. Bulk runs confirm how many accounts will be processed, and each user can only run agents against accounts within their own purview.

Global – October 12, 2026 -- EverHealth's Marley Wagner has laid out a staged coaching roadmap for customer success managers (CSMs): build coaching habits in the first 30-60 days, then shift to a team-wide coaching culture, with six months as the checkpoint for results.

Live customer situations become coaching material in the first 30-60 days

Wagner, head of customer success programs and strategy at EverHealth, tells managers to review renewal conversations, quarterly business reviews (QBRs), executive business reviews (EBRs), difficult customer emails, angry customer calls and executive conversations. CSMs lead these interactions, and managers join and ask questions rather than take over. Afterward, the manager reviews the CSM's decision-making: what went right and what could improve.

The roadmap also tells managers to normalize uncertainty. Wagner's example phrase for CSMs is: "Let me validate that and come back with the best path forward."

Global – October 12, 2026 -- ChurnZero CEO You Mon Tsang predicts the average customer success manager (CSM) will gain 25-50% more bandwidth per day by the end of 2026 through AI, provided teams avoid the most common adoption error: automating the whole operation at once.

ChurnZero VP of Customer Success Lukas Alexander laid out the argument on the “Customer Success Talks” podcast. He cited two obstacles. The first is AI overreach, where handing too much decision-making to AI could damage long-term customer relationships. The second is balancing automation with a personal touch, because CS teams depend on lasting partnerships rather than the transactional relationships typical of sales and marketing.

Global – October 12, 2026 -- Customer success (CS) teams with a dedicated customer success platform (CSP) reported 100% net revenue retention (NRR), versus 94% for organizations without one, according to ChurnZero's Customer Revenue Leadership Study. The figure was cited during a webinar in which three CS executives each backed a dedicated CSP over a CRM module as leaders plan for 2027.

Gartner survey finds 91% of service leaders feel more pressure to adopt AI

Ravi Pimplaskar, Senior Director of Revenue Marketing at ChurnZero, cited a Gartner survey in which 91% of customer service and support leaders reported increased pressure to adopt AI. The pressure runs in both directions. Boardrooms are issuing mandates, while CSMs want AI to cut heavy administrative workloads, said Lukas Alexander, VP of Customer Success at ChurnZero.

Vancouver – October 12, 2026 -- Anthropic committed $250 million across two new initiatives in the past two weeks, while OpenAI rolled out GPT-6 to every ChatGPT user. Most announcements from the two private AI developers targeted large organizations and government customers.

Anthropic launches cheaper Haiku 5.5 and funds two programs worth $250 million

Anthropic introduced Claude Haiku 5.5 on October 7, calling it "the cheapest, fastest, and most capable small model we've ever released." The company said the model costs about 75% less to run on average than Haiku 4.5. It is available on Amazon Web Services, Google Cloud and Microsoft Azure.

Santa Clara – October 12, 2026 -- HCLTech has signed a Global Premier Partnership with Anthropic and will set up a dedicated Anthropic Business Unit with a Center of Excellence (CoE) to speed enterprise deployments of Claude, with a focus on safety, cybersecurity and governance in Agentic AI.

HCLTech's new unit will offer sandbox environments for Claude deployments

The unit will build Agentic AI solutions and provide secure sandbox environments for enterprise Claude deployments through FDEs. HCLTech's services teams will also build industry solutions and offerings powered by Claude, Cowork and Claude Code.

HCLTech will help clients adopt AI-native engineering practices, train their workforces and build the organizational capabilities needed to run Agentic AI safely at scale.

San Jose – October 12, 2026 -- Cablenet Communication Systems plc, the second largest fixed network operator in Cyprus, is modernizing its DOCSIS broadband access network with Harmonic's cOS virtualized broadband platform, Harmonic (NASDAQ: HLIT) announced. The deployment is designed to strengthen gigabit service capability, simplify operations and lower operating expenses.

Distributed access architecture with Oyster nodes underpins higher speed tiers

Cablenet is deploying cOS in a distributed access architecture (DAA) with low-power Oyster nodes. The operator can introduce significantly higher speeds across its footprint and scale services as subscriber demand grows. The software-based platform also preserves flexibility for Cablenet's longer-term multi-technology network strategy.

Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.

Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online

The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.

Management and five retina specialists to address commercial readiness

REGENXBIO management and retina specialists will discuss the treatment landscape, unmet need, the ATMOSPHERE and ASCENT pivotal trials, and the commercial readiness of sura-vec in wet AMD.

Five key opinion leaders are scheduled to appear:

Dublin – October 12, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.

Ten-author analysis targets liver transplant-ineligible patients

The presentation is titled "Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial." Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, is the presenting author. Nine co-authors are listed, including Kavish Patidar, Kevin Regner and Nneka N. Ufere.

Laval – October 12, 2026 -- A six-month pilot of a standardized cirrhosis clinical pathway raised follow-up office visit adherence by 9.0% in relative terms, to 51.1% from 46.9%, across 4,251 patients in five community gastroenterology practices, Bausch Health Companies Inc. and its GI unit Salix Pharmaceuticals announced.

The results will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, held October 9-14, 2026, in Nashville, Tennessee. The companies describe the findings as preliminary until presented and evaluated in peer-reviewed publications.